Seaweed-Derived Peptides for Blood Pressure, Diabetes, and Oxidative Stress: What Research Shows

Peptides isolated from seaweed proteins have demonstrated ACE-inhibiting (blood pressure-lowering), antioxidant, and antidiabetic activities in laboratory studies. Multiple seaweed species have yielded bioactive peptides through enzymatic hydrolysis that could serve as functional food ingredients or drug candidates for cardiovascular disease and diabetes prevention. However, most evidence comes from in vitro studies, and large-scale production, in vivo validation, and safety testing are still needed.

This is a review article summarizing recent research on the production, isolation, and health effects of bioactive peptides derived from seaweed proteins. The authors surveyed published studies on ACE inhibition, antihypertensive, antioxidant, and antidiabetic properties of these peptides.

Cardiovascular disease and diabetes are the leading causes of death globally. Finding new peptide-based treatments from sustainable sources like seaweed could provide affordable, food-derived therapeutic options. Seaweed is abundant, renewable, and already part of many diets worldwide, making it an attractive platform for bioactive peptide production.

The search for bioactive peptides from food sources is a growing field in nutraceutical and pharmaceutical research. Seaweed is particularly interesting because it's sustainable, widely available, and rich in unique proteins not found in land-based plants. If seaweed peptides can be validated in human studies, they could become a new category of functional food ingredients for preventing the world's two leading killers.

Most studies reviewed were conducted in laboratory settings (in vitro), with limited in vivo or human clinical data. Large-scale production methods haven't been established. Peptide stability during digestion, interactions with other drugs or foods, and long-term safety are still unknown.